CENTOGENE’s mission is to enable the healing of 100 rare species
- The company has significant potential for value creation to contribute to the diagnosis of rare diseases and allow the development of new therapies.
- Focuses on exploiting its unique bio / database focused on rare diseases to accelerate the development of orphan drugs in partnership with bio / pharmaceutical companies
- Clear priorities defined for disease therapeutic areas, focusing on rare neurological (CNS) and metabolic disorders
- Medium-term objectives set to reach 1 million patients in the bio / database and 10 complete disease models for an R&D partnership on rare diseases
CAMBRIDGE, Massachusetts and ROSTOCK, Germany and BERLIN, June 22, 2021 (GLOBE NEWSWIRE) – Centogene NV (Nasdaq: CNTG), a commercial company focused on generating data-driven information to diagnose, understand and treat rare diseases , will hold its first virtual event for investors, presented by its new management team.
Andrin Oswald, MD, CEO of CENTOGENE, said: “Over the past 15 years, CENTOGENE has built a unique expertise and has become the leading provider of data-driven information, exclusively focused on rare genetic diseases. We are now entering our next phase of growth – curing 100 rare diseases over the next 10 years. This represents the potential to contribute significantly to reducing the burden of rare diseases. “
“This next chapter is fueled by our unparalleled genomics knowledge, the world’s largest rare disease-centric database / biobank, our global footprint and our strong established network of physicians, partners and patients. Together with our AI and multiomics tools, this places us at the heart of precision medicine for genetically related rare diseases – through the ability to unlock the complexities of patient biology to effectively diagnose, understand and treat these diseases. Given that the rare disease market is large and often overlooked, and our capabilities will contribute significantly to the sector, we believe this new direction will provide substantial opportunities for value creation.
Diagnose. Understand. Treat.
Founded in 2006, CENTOGENE has long been known for its expertise in the field of rare disease genetics – helping over 600,000 patients and creating a database / bio focused on rare diseases. Aspiring to reduce the heavy burden of rare diseases through data-driven insight, the company has established itself as the partner of choice for patients, physicians and pharmaceutical partners.
At the virtual investor event, the company will announce its strategic, multi-pronged approach to diagnosing, understanding and treating rare diseases by finding, connecting and studying patients and their biology from around the world.
Strategic priorities to accelerate the discovery, development and access to orphan drugs
- Focus on the creation of the company’s bio / database with multimodal data for priority pathological areas; medium-term goal of more than one million patients
- Further establish the multiomics platform to overcome the various challenges of diagnostics, patient identification, clinical trials, and drug discovery and development
- Develop 10 complete disease models, including mid-term cell lines
- Partner in areas of therapeutic interest, including two major strategic partnership agreements aimed at enabling the development of therapies in the coming years
- Initial priority diseases in the areas of metabolic and neurological disorders include Gaucher and genetic Parkinson’s disease
As the Company continues to drive targeted innovation, its priorities remain the same: investing and developing its Diagnostics and Pharma segments to transform clinical and genetic data science into medical solutions for patients with rare diseases.
In the two core business segments of CENTOGENE, the Company has established a unique positioning and laid the foundation for the expected growth and impact in the short, medium and long term. Leveraging its expertise in the field of rare diseases while developing its technological capabilities, CENTOGENE is confident in its ability to cure 100 rare diseases.
Register for virtual Investor Event
The Company will host the Virtual Investor Event today, June 22, 2021, 9:00 a.m. to 11:00 a.m. EDT / 3:00 p.m. to 5:00 p.m. CEST. To register, visit: https://www.centogene.com/virtual-investor-event.html
Participants can also access the conference call by dialing the toll-free number in the United States +1 855 979 6654 or in the United Kingdom +44 (0) 800 640 6441 up to 10 minutes before the start of the call and by providing the conference ID number 182810. Calling another participant The numbers in digits can be found on the event registration page.
CENTOGENE engages in the diagnosis and research around rare diseases by transforming clinical, genetic and multiomic data from the real world to diagnose, understand and treat rare diseases. Our goal is to streamline treatment decisions and accelerate the development of new orphan drugs using our extensive knowledge and data on rare diseases. CENTOGENE has developed an exclusive global rare disease platform based on our real-world data repository with over 3.9 billion weighted data points from approximately 600,000 patients representing over 120 different countries as of December 31, 2020.
The Company’s platform includes epidemiological, phenotypic and genetic data that reflect a global population, as well as a biobank of blood samples and cell cultures from patients. CENTOGENE believes it is the only platform focused on comprehensive, multi-level data analysis to improve understanding of rare inherited diseases. It enables better identification and stratification of patients and their underlying diseases to enable and accelerate the discovery, development and access to orphan drugs. As of December 31, 2020, the Company was collaborating with more than 30 pharmaceutical partners.
Important notice and disclaimer
This press release contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express opinions, expectations, beliefs, plans , the objectives, assumptions or projections of the company. regarding future events or future results, unlike statements that reflect historical facts. Examples include discussing our strategies, financing plans, growth opportunities, and market growth. In some cases, you may identify these forward-looking statements by words such as “anticipate”, “intend”, “believe”, “estimate”, “plan”, “seek”, “plan” or “‘, “Will”, “would”, “could” or “should”, the negative of these terms or similar expressions. Forward-looking statements are based on the current beliefs and assumptions of management and on information currently available to the Company. However, these forward-looking statements are not guarantees of our performance and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other varying circumstances, such as negative global economic conditions and the continued instability and volatility of global financial markets, the effects of the COVID-19 pandemic on our business and our results of operations, possible changes in current and proposed legislation, regulations and government policies, pressures of increasing competition and consolidation in our industry, expenses and uncertainty of regulatory approval, including from the United States Food and Drug Administration, our reliance on third parties and collaborative partners, including our ability to manage growth and forge new customer relationships, our reliance on l ” regard to the rare disease industry, our ability to manage international expansion, our dependence on the key personnel, our reliance on intellectual property protection, fluctuations in our operating results due to the effect of currency exchange rates or other factors. Such risks and uncertainties may cause statements to be inaccurate, and readers are cautioned not to place undue reliance on such statements. Many of these risks are beyond the control of the Company and could cause its actual results to differ materially from those expected to occur. The forward-looking statements included in this press release are made only as of the date hereof. The Company does not undertake, and specifically disclaims, any obligation to update such statements or to publicly announce the results of any revision of such statements to reflect future events or developments, except as required by law. .
For more information, please see the Risk Factors section of our Annual Report for the year ended December 31, 2020, Form 20-F filed with the SEC on April 15, 2021, and other reports. and documents provided or filed with the United States Securities Commission (SEC). You can obtain these documents by visiting EDGAR on the SEC’s website at www.sec.gov.